Abstract
Janus kinase-2 (JAK2) is a non-receptor tyrosine kinase that serves key roles as the intracellular signaling effector of the cytokine receptor, such as mediating effects of leptin, erythropoietin, interferon, and growth hormone. A lot of molecular underlying mechanisms of JAK2 participation are known, however, additional signaling mechanisms of its activation, regulation, and pleiotropic signaling roles are still being explored. Here, we review the current knowledge of JAK2-mediated cellular signaling at the molecular level. In the beginning, we will focus on the recent advances in JAK2 activation and regulation. A part of our review focuses on the JAK2 involvement in various diseases/conditions. Recent advances highlight the molecular regulatory mechanisms utilized by the JAK2 signaling, thus, enabling to consider alternative therapeutic strategies to treat various diseases/conditions mediated by JAK2 by using it as a therapeutic target.
Keywords: Jak2, STAT, protein kinases, hormones, intracellular signaling, cytokine receptor.
Current Molecular Medicine
Title:JAK2-mediated Intracellular Signaling
Volume: 21 Issue: 5
Author(s): Mentor Sopjani*, Rifat Morina, Valdet Uka, Nguyen Thi Xuan and Miribane Dërmaku-Sopjani*
Affiliation:
- Faculty of Medicine, University of Prishtina, 10 000, Prishtine,Kosova
- Faculty of Natural Sciences and Mathematics, University of Prishtina, 10 000, Prishtinë,Kosova
Keywords: Jak2, STAT, protein kinases, hormones, intracellular signaling, cytokine receptor.
Abstract: Janus kinase-2 (JAK2) is a non-receptor tyrosine kinase that serves key roles as the intracellular signaling effector of the cytokine receptor, such as mediating effects of leptin, erythropoietin, interferon, and growth hormone. A lot of molecular underlying mechanisms of JAK2 participation are known, however, additional signaling mechanisms of its activation, regulation, and pleiotropic signaling roles are still being explored. Here, we review the current knowledge of JAK2-mediated cellular signaling at the molecular level. In the beginning, we will focus on the recent advances in JAK2 activation and regulation. A part of our review focuses on the JAK2 involvement in various diseases/conditions. Recent advances highlight the molecular regulatory mechanisms utilized by the JAK2 signaling, thus, enabling to consider alternative therapeutic strategies to treat various diseases/conditions mediated by JAK2 by using it as a therapeutic target.
Export Options
About this article
Cite this article as:
Sopjani Mentor *, Morina Rifat , Uka Valdet , Xuan Thi Nguyen and Dërmaku-Sopjani Miribane *, JAK2-mediated Intracellular Signaling, Current Molecular Medicine 2021; 21 (5) . https://dx.doi.org/10.2174/1566524020666201015144702
DOI https://dx.doi.org/10.2174/1566524020666201015144702 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Resveratrol and Cancer Treatment: Is Hormesis a Yet Unsolved Matter?
Current Pharmaceutical Design Biochemical Markers of Autoimmune Diseases of the Nervous System
Current Pharmaceutical Design Inhibition of microRNA-155 Alleviates Cognitive Impairment in Alzheimer’s Disease and Involvement of Neuroinflammation
Current Alzheimer Research Lymphoproliferative Lesions in IgG4-Related Disease
Current Immunology Reviews (Discontinued) Absorption, Disposition and Pharmacokinetics of Solid Lipid Nanoparticles
Current Drug Metabolism Nitric Oxide as a Marker for Levo-Thyroxine Therapy in Subclinical Hypothyroid Patients
Current Vascular Pharmacology Monoclonal Antibodies in the Treatment of Systemic Lupus Erythematosus
Current Drug Targets Thalidomide Improves Psoriasis-like Lesions and Inhibits Cutaneous VEGF Expression without Alteration of Microvessel Density in Imiquimod- induced Psoriatic Mouse Model
Current Vascular Pharmacology Inhibitors of Endocannabinoid Degradation as Potential Therapeutic Agents
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Editorial [ Murine Atherosclerosis (Part III) Guest Editor: Godfrey S. Getz ]
Current Drug Targets Endotoxin Recognition Molecules MD-2 and Toll-like Receptor 4 as Potential Targets for Therapeutic Intervention of Endotoxin Shock
Current Drug Targets - Inflammation & Allergy Assessment of Short-Term Changes Induced by a Dermatophagoides pteronyssinus Extract on Asthmatic Patients. Randomised, Double-Blind, Placebo-Controlled Trial
Current Drug Delivery Role of PPAR in Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Subject Index To Volume 3
Current Neurovascular Research Preterm Labour: An Overview of Current and Emerging Therapeutics
Current Medicinal Chemistry Chromogranin A as a Calcium-Binding Precursor for a Multitude of Regulatory Peptides for the Immune, Endocrine and Metabolic Systems
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents CTLA-4Ig: Uses and Future Directions
Recent Patents on Inflammation & Allergy Drug Discovery The Soluble CTLA-4 Receptor and its Emerging Role in Autoimmune Diseases
Current Immunology Reviews (Discontinued) The Role of the Endocannabinoid System in Alzheimers Disease: Facts and Hypotheses
Current Pharmaceutical Design Oxidative Stress, HDL and Atherosclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry